Use of continuous-infusion 5-fluorouracil (5-FU) for the treatment of metastatic breast cancer has met with some success in recent years. In order to build on this experience, investigators at the Royal Marsden Hospital and
Ian E. Smith, MD, FRCP, FRCPE
Advertisement
Articles by Ian E. Smith, MD, FRCP, FRCPE
Letrozole (Femara) is a nonsteroidal aromatase inhibitor that is approximately 10,000 times as potent as aminoglutethimide in vivo. Two pivotal multinational phase III trials have compared letrozole (0.5 and 2.5 mg/d) against megestrol acetate and aminoglutethimide, respectively, in patients with locally advanced or metastatic breast cancer.
Advertisement
Latest Updated Articles
- Epirubicin, Cyclophosphamide, and UFT Plus Oral Calcium Folinate in Advanced Breast Cancer
Published: July 1st 1999 | Updated:
- Pivotal Trials of Letrozole: A New Aromatase Inhibitor
Published: March 2nd 1998 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
177Lu-PSMA-I&T/223Ra Display Safety and Feasibility in Metastatic CRPC
2
Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC
3
H.R. 2541: Examining Its Legislative Impact on Radiopharmaceutical Practice
4
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC
5
